Cytomegalovirus Infection Treatment Market - 2023-2031
The Cytomegalovirus Infection Treatment Market was valued at US$ 516.36 million in 2023 and is anticipated to reach US$ 858.65 million by 2031, at a CAGR of 0.067 from 2026 to 2032.
The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Cytomegalovirus Infection Treatment Market.
This report delivers a comprehensive overview of the Cytomegalovirus Infection Treatment Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Cytomegalovirus Infection Treatment Market. The Cytomegalovirus Infection Treatment Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2023–2031.
Cytomegalovirus Infection Treatment Market Scope:
By Drug Type
This report delivers a comprehensive overview of the Cytomegalovirus Infection Treatment Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Cytomegalovirus Infection Treatment Market. The Cytomegalovirus Infection Treatment Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2023–2031.
This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Regional Analysis:
The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Cytomegalovirus Infection Treatment Market.
This report delivers a comprehensive overview of the Cytomegalovirus Infection Treatment Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Cytomegalovirus Infection Treatment Market. The Cytomegalovirus Infection Treatment Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2023–2031.
Cytomegalovirus Infection Treatment Market Scope:
By Drug Type
- Cytovene
- Valcyte
- Foscarnet
- Vistide
- Others
- Stem Cell Transplantation
- Organ Transplantation
- Congenital CMV infection
- Others
- Retinitis
- Pneumonia
- Esophagitis
- Colitis
- Others
- Serologic Test
- Polymerase Chain Reaction (PCR) Test
- Others
- Oral
- Intravenous
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
- Hospitals
- Specialty Clinics
- Homecare
- Others
- Merck & Co., Inc
- F. Hoffmann-La Roche Ltd
- Fresenius Kabi Canada
- GSK Plc
- AiCuris Anti-infective Cures AG
- Chimerix, Inc
- Abbott
- Bio-Rad Laboratories, Inc
- Takeda Pharmaceutical Company Limited
- Teva Pharmaceutical Industries Ltd
This report delivers a comprehensive overview of the Cytomegalovirus Infection Treatment Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Cytomegalovirus Infection Treatment Market. The Cytomegalovirus Infection Treatment Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2023–2031.
This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Regional Analysis:
- North America (U.S., Canada, Mexico)
- Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
- Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
- South America (Colombia, Brazil, Argentina, Rest of South America)
- Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)
- Increase Your Customer Base by 3X using our Partner Identification tool
- Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.
- Identify high potential M&A targets based on synergies, market positioning and growth trajectory.
- Prioritize partners by strategic fit rather than general capability.
- Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.
- Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.
- White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.
- Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.
- Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.
- Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
1. METHODOLOGY AND SCOPE
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. DEFINITION AND OVERVIEW
3. EXECUTIVE SUMMARY
3.1. Snippet by Drug Type
3.2. Snippet by Application
3.3. Snippet by Infection
3.4. Snippet by Diagnosis Test
3.5. Snippet by Route of Administration
3.6. Snippet by Distribution Channel
3.7. Snippet by End-User
3.8. Snippet by Region
4. DYNAMICS
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing Prevalence of Viral Infections
4.1.1.2. Rising Prevalence of CMV Retinitis and Congenital CMV infection
4.1.1.3. Growing Government Initiatives for Creating Awareness Regarding Treatments
4.1.1.4. The Growing Demand for Personalized Medicine
4.1.2. Restraints
4.1.2.1. Adverse Effects and Risks Related to Cytomegalovirus Drugs
4.1.2.2. High Cost Associated with the Treatment
4.1.3. Opportunity
4.1.4. Impact Analysis
5. INDUSTRY ANALYSIS
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Unmet Needs
5.6. PESTEL Analysis
5.7. Patent Analysis
5.8. SWOT Analysis
6. COVID-19 ANALYSIS
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. BY DRUG TYPE
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
7.1.2. Market Attractiveness Index, By Drug Type
7.2. Cytovene*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Valcyte
7.4. Foscarnet
7.5. Vistide
7.6. Others
8. BY APPLICATION
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
8.1.2. Market Attractiveness Index, By Application
8.2. Stem Cell Transplantation*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Organ Transplantation
8.4. Congenital CMV infection
8.5. Others
9. BY INFECTION
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Infection
9.1.2. Market Attractiveness Index, By Infection
9.2. Retinitis*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Pneumonia
9.4. Esophagitis
9.5. Colitis
9.6. Others
10. BY DIAGNOSIS TEST
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnosis Test
10.1.2. Market Attractiveness Index, By Diagnosis Test
10.2. Serologic Test*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Polymerase Chain Reaction (PCR) Test
10.4. Others
11. BY ROUTE OF ADMINISTRATION
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.1.2. Market Attractiveness Index, By Route of Administration
11.2. Oral*
11.2.1. Introduction
11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
11.3. Intravenous
12. BY DISTRIBUTION CHANNEL
12.1. Introduction
12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
12.1.2. Market Attractiveness Index, By Distribution Channel
12.2. Hospital Pharmacy*
12.2.1. Introduction
12.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
12.3. Retail Pharmacy
12.4. Online Pharmacy
12.5. Others
13. BY END-USER
13.1. Introduction
13.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
13.1.2. Market Attractiveness Index, By End-User
13.2. Hospitals*
13.2.1. Introduction
13.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
13.3. Specialty Clinics
13.4. Homecare
13.5. Others
14. BY REGION
14.1. Introduction
14.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
14.1.2. Market Attractiveness Index, By Region
14.2. North America
14.2.1. Introduction
14.2.2. Key Region-Specific Dynamics
14.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
14.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
14.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Infection
14.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnosis Test
14.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
14.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
14.2.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
14.2.10. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
14.2.10.1. U.S.
14.2.10.2. Canada
14.2.10.3. Mexico
14.3. Europe
14.3.1. Introduction
14.3.2. Key Region-Specific Dynamics
14.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
14.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
14.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Infection
14.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnosis Test
14.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
14.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
14.3.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
14.3.10. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
14.3.10.1. Germany
14.3.10.2. UK
14.3.10.3. France
14.3.10.4. Italy
14.3.10.5. Spain
14.3.10.6. Rest of Europe
14.4. South America
14.4.1. Introduction
14.4.2. Key Region-Specific Dynamics
14.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
14.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
14.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Infection
14.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnosis Test
14.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
14.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
14.4.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
14.4.10. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
14.4.10.1. Brazil
14.4.10.2. Argentina
14.4.10.3. Rest of South America
14.5. Asia-Pacific
14.5.1. Introduction
14.5.2. Key Region-Specific Dynamics
14.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
14.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
14.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Infection
14.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnosis Test
14.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
14.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
14.5.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
14.5.10. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
14.5.10.1. China
14.5.10.2. India
14.5.10.3. Japan
14.5.10.4. South Korea
14.5.10.5. Rest of Asia-Pacific
14.6. Middle East and Africa
14.6.1. Introduction
14.6.2. Key Region-Specific Dynamics
14.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
14.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
14.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Infection
14.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnosis Test
14.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
14.6.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
14.6.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
15. COMPETITIVE LANDSCAPE
15.1. Competitive Scenario
15.2. Market Positioning/Share Analysis
15.3. Mergers and Acquisitions Analysis
16. COMPANY PROFILES
16.1. Merck & Co., Inc *
16.1.1. Company Overview
16.1.2. Product Portfolio and Description
16.1.3. Financial Overview
16.1.4. Key Developments
16.2. F. Hoffmann-La Roche Ltd
16.3. Fresenius Kabi Canada
16.4. GSK Plc
16.5. AiCuris Anti-infective Cures AG
16.6. Chimerix, Inc
16.7. Abbott
16.8. Bio-Rad Laboratories, Inc
16.9. Takeda Pharmaceutical Company Limited
16.10. Teva Pharmaceutical Industries Ltd (LIST NOT EXHAUSTIVE)
17. APPENDIX
17.1. About Us and Services
17.2. Contact Us
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. DEFINITION AND OVERVIEW
3. EXECUTIVE SUMMARY
3.1. Snippet by Drug Type
3.2. Snippet by Application
3.3. Snippet by Infection
3.4. Snippet by Diagnosis Test
3.5. Snippet by Route of Administration
3.6. Snippet by Distribution Channel
3.7. Snippet by End-User
3.8. Snippet by Region
4. DYNAMICS
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing Prevalence of Viral Infections
4.1.1.2. Rising Prevalence of CMV Retinitis and Congenital CMV infection
4.1.1.3. Growing Government Initiatives for Creating Awareness Regarding Treatments
4.1.1.4. The Growing Demand for Personalized Medicine
4.1.2. Restraints
4.1.2.1. Adverse Effects and Risks Related to Cytomegalovirus Drugs
4.1.2.2. High Cost Associated with the Treatment
4.1.3. Opportunity
4.1.4. Impact Analysis
5. INDUSTRY ANALYSIS
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Unmet Needs
5.6. PESTEL Analysis
5.7. Patent Analysis
5.8. SWOT Analysis
6. COVID-19 ANALYSIS
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. BY DRUG TYPE
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
7.1.2. Market Attractiveness Index, By Drug Type
7.2. Cytovene*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Valcyte
7.4. Foscarnet
7.5. Vistide
7.6. Others
8. BY APPLICATION
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
8.1.2. Market Attractiveness Index, By Application
8.2. Stem Cell Transplantation*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Organ Transplantation
8.4. Congenital CMV infection
8.5. Others
9. BY INFECTION
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Infection
9.1.2. Market Attractiveness Index, By Infection
9.2. Retinitis*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Pneumonia
9.4. Esophagitis
9.5. Colitis
9.6. Others
10. BY DIAGNOSIS TEST
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnosis Test
10.1.2. Market Attractiveness Index, By Diagnosis Test
10.2. Serologic Test*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Polymerase Chain Reaction (PCR) Test
10.4. Others
11. BY ROUTE OF ADMINISTRATION
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.1.2. Market Attractiveness Index, By Route of Administration
11.2. Oral*
11.2.1. Introduction
11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
11.3. Intravenous
12. BY DISTRIBUTION CHANNEL
12.1. Introduction
12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
12.1.2. Market Attractiveness Index, By Distribution Channel
12.2. Hospital Pharmacy*
12.2.1. Introduction
12.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
12.3. Retail Pharmacy
12.4. Online Pharmacy
12.5. Others
13. BY END-USER
13.1. Introduction
13.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
13.1.2. Market Attractiveness Index, By End-User
13.2. Hospitals*
13.2.1. Introduction
13.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
13.3. Specialty Clinics
13.4. Homecare
13.5. Others
14. BY REGION
14.1. Introduction
14.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
14.1.2. Market Attractiveness Index, By Region
14.2. North America
14.2.1. Introduction
14.2.2. Key Region-Specific Dynamics
14.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
14.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
14.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Infection
14.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnosis Test
14.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
14.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
14.2.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
14.2.10. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
14.2.10.1. U.S.
14.2.10.2. Canada
14.2.10.3. Mexico
14.3. Europe
14.3.1. Introduction
14.3.2. Key Region-Specific Dynamics
14.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
14.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
14.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Infection
14.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnosis Test
14.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
14.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
14.3.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
14.3.10. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
14.3.10.1. Germany
14.3.10.2. UK
14.3.10.3. France
14.3.10.4. Italy
14.3.10.5. Spain
14.3.10.6. Rest of Europe
14.4. South America
14.4.1. Introduction
14.4.2. Key Region-Specific Dynamics
14.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
14.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
14.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Infection
14.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnosis Test
14.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
14.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
14.4.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
14.4.10. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
14.4.10.1. Brazil
14.4.10.2. Argentina
14.4.10.3. Rest of South America
14.5. Asia-Pacific
14.5.1. Introduction
14.5.2. Key Region-Specific Dynamics
14.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
14.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
14.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Infection
14.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnosis Test
14.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
14.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
14.5.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
14.5.10. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
14.5.10.1. China
14.5.10.2. India
14.5.10.3. Japan
14.5.10.4. South Korea
14.5.10.5. Rest of Asia-Pacific
14.6. Middle East and Africa
14.6.1. Introduction
14.6.2. Key Region-Specific Dynamics
14.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
14.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
14.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Infection
14.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnosis Test
14.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
14.6.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
14.6.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
15. COMPETITIVE LANDSCAPE
15.1. Competitive Scenario
15.2. Market Positioning/Share Analysis
15.3. Mergers and Acquisitions Analysis
16. COMPANY PROFILES
16.1. Merck & Co., Inc *
16.1.1. Company Overview
16.1.2. Product Portfolio and Description
16.1.3. Financial Overview
16.1.4. Key Developments
16.2. F. Hoffmann-La Roche Ltd
16.3. Fresenius Kabi Canada
16.4. GSK Plc
16.5. AiCuris Anti-infective Cures AG
16.6. Chimerix, Inc
16.7. Abbott
16.8. Bio-Rad Laboratories, Inc
16.9. Takeda Pharmaceutical Company Limited
16.10. Teva Pharmaceutical Industries Ltd (LIST NOT EXHAUSTIVE)
17. APPENDIX
17.1. About Us and Services
17.2. Contact Us
